Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Hiroki Kawashima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3720-781X; OpenAlex author ID A5060492542, A5074762441, A5152923120. Sources: OpenAlex.

Their work

Papers
31 (first author 5, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 8 papers · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 10 papers

Papers 31

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  2. Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Control… Co-author DOI 10.1002/jhbp.70150↗
  3. Pretreatment Contrast-Enhanced Harmonic EUS Predicts Pathological Response and Recurrence-Free Survival After Multimodal Treatment in Resectable Pancreatic Can… Last author DOI 10.1002/jhbp.70180↗
  4. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  5. Response to the letter to the editor regarding "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and ident… Co-author DOI 10.1016/j.pan.2025.12.005↗
  6. Clinical characteristics and therapeutic implications of MTAP deletion in pancreatic cancer: A nationwide genomic analysis. Co-author DOI 10.1016/j.pan.2026.07.015↗
  7. Endoscopic ultrasound-guided fiducial marker placement for image-guided proton beam therapy in pancreatic cancer: implications for positional accuracy and posi… Last author DOI 10.1093/jrr/rrag082↗
  8. FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study. Co-author DOI 10.1111/cas.70351↗
  9. Operator-rated puncture performance and first-pass lesion tissue area in pancreatic ductal adenocarcinoma: an exploratory single-center sub-analysis of endosco… Last author DOI 10.21203/rs.3.rs-11273454/v1↗
  10. Utility of endoscopic ultrasonography elastography as a predictive tool for post-treatment recurrence of resectable pancreatic cancer treated with neoadjuvant … Last author DOI 10.5946/ce.2025.414↗
  11. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Last author DOI 10.5946/ce.2022.278↗
  12. Usefulness of Endoscopic Ultrasound Elastography and Contrast-Enhanced Endoscopic Ultrasound in the Diagnosis of Pancreatic Cancer of 10 mm or Less Last author DOI 10.21203/rs.3.rs-3014153/v1↗
  13. Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics13020215↗
  14. Comparison of contrast-enhanced transabdominal ultrasonography following endoscopic ultrasonography with GD-EOB-DTPA-enhanced MRI for the sequential diagnosis … Last author DOI 10.1002/jhbp.1097↗
  15. Comparison of outcomes between secondary fully covered and uncovered self-expandable metal stents in the treatment of recurrent biliary obstruction of pancreat… First author DOI 10.1007/s00464-021-08981-2↗
  16. Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment. Co-author DOI 10.1016/j.jgo.2022.09.005↗
  17. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  18. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  19. Author Correction: Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41598-022-21219-y↗
  20. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  21. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial … Co-author DOI 10.1186/s12885-022-09272-2↗
  22. Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.12.022↗
  23. Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41598-021-86979-5↗
  24. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. First author DOI 10.1111/jgh.15163↗
  25. Diagnosis of vascular invasion in pancreatic ductal adenocarcinoma using endoscopic ultrasound elastography. First author DOI 10.1186/s12876-020-01228-9↗
  26. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer. First author DOI 10.1159/000492388↗
  27. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  28. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  29. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1186/s12885-018-4453-z↗
  30. The prognostic factors and trajectory of HRQOL in patients with pancreatic cancer who received psychiatric intervention. First author DOI 10.1111/jgh.13172↗
  31. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Co-author DOI 10.1007/s00280-010-1531-6↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuya Ishikawa · 25 shared papers, 2018–2026 · strength 4.39
  2. Tadashi Iida · 15 shared papers, 2020–2026 · strength 2.65
  3. Eizaburo Ohno · 20 shared papers, 2011–2024 · strength 2.33
  4. Yasuyuki Mizutani · 11 shared papers, 2022–2026 · strength 2.18
  5. Kentaro Yamao · 7 shared papers, 2023–2026 · strength 1.86
  6. Osamu Maeda · 8 shared papers, 2018–2026 · strength 1.45
  7. Yoshiki Hirooka · 13 shared papers, 2011–2023 · strength 1.27
  8. Yoshihisa Takada · 4 shared papers, 2026 · strength 1.14
  9. Mitsuhiro Fujishiro · 9 shared papers, 2020–2022 · strength 1.10
  10. Junpei Yamaguchi · 6 shared papers, 2018–2026 · strength 0.97
  11. Yukihiro Yokoyama · 6 shared papers, 2018–2026 · strength 0.97
  12. Tomoki Ebata · 4 shared papers, 2022–2026 · strength 0.84
  13. Kazuyuki Mizuno · 2 shared papers, 2026 · strength 0.69
  14. Yuichi Kano · 2 shared papers, 2026 · strength 0.59
  15. Suguru Yamada · 4 shared papers, 2018–2026 · strength 0.56
  16. Kunio Kataoka · 4 shared papers, 2020–2024 · strength 0.55
  17. Yasuhiro Kodera · 5 shared papers, 2018–2024 · strength 0.53
  18. Tsutomu Fujii · 4 shared papers, 2018–2026 · strength 0.49
  19. Masakatsu Yoshikawa · 4 shared papers, 2020–2022 · strength 0.47
  20. Atsushi Enomoto · 3 shared papers, 2022 · strength 0.38
  21. Masamichi Hayashi · 3 shared papers, 2018–2026 · strength 0.36
  22. Mamoru Takenaka · 1 shared paper, 2026 · strength 0.36
  23. Shinji Naganawa · 3 shared papers, 2018–2026 · strength 0.36
  24. Hiroya Matsumoto · 1 shared paper, 2026 · strength 0.36
  25. Yuichi Ando · 1 shared paper, 2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.